Spruce Biosciences has patented a method for treating PCOS-FAH by administering a CRF1 antagonist. The treatment targets elevated adrenal androgens, addressing symptoms like hirsutism and infertility. The patent provides new compounds and methods for managing PCOS effectively. GlobalData’s report on Spruce Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spruce Biosciences, Peptide pharmacophores was a key innovation area identified from patents. Spruce Biosciences's grant share as of January 2024 was 16%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11858932B2) discloses a method for treating polycystic ovary syndrome with functional adrenal hyperandrogenism (PCOS-FAH) by administering a CRF1 antagonist or a pharmaceutically acceptable salt thereof. The CRF1 antagonist is a compound of Formula (I) and can be administered in various doses ranging from 5 mg to 400 mg total daily dose to the subject. The method aims to reduce levels of adrenocorticotropic hormone (ACTH), dehydroepiandrosterone sulfate (DHEAS), and other androgen-related hormones by at least 10% from baseline.
Furthermore, the patent claims specify that the compound of Formula (I) can be administered at a dose between 1 mg/day and 200 mg/day and can be in the form of a pharmaceutical composition, such as microparticles, capsules, or tablets. The method is applicable to both pediatric and adult patients, highlighting its potential for a wide range of individuals suffering from PCOS-FAH. By targeting specific hormone levels and providing detailed dosing information, this patented method offers a precise and potentially effective treatment option for individuals in need of managing the symptoms associated with PCOS-FAH.
To know more about GlobalData’s detailed insights on Spruce Biosciences, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
